Zosano Pharma Corporation Loss Submission Form

See If You Qualify For Monetary Reward

Enter your details and we will calculate your loss for you

Submit Transaction Detail Now (Optional)

- OR -

    An attorney-client relationship is not created with the submission of this form, nor an obligation on the part of Levi & Korsinsky or you to file a lead plaintiff motion in this matter . The information you submit is held as confidential. If, in its sole discretion, Levi & Korsinsky believes that you might be an appropriate lead plaintiff candidate, Levi & Korsinsky will contact you to discuss the matter and whether to establish an attorney client relationship. By submitting this form, you are authorizing us to contact you regarding this case and/or future cases. Additionally, by submitting this form, you agree to receive an email providing you with login details for CORE (Compensation Recovery Monitoring System) to help you monitor and track your securities. This is a complimentary service. Thank you for submitting your details to Levi & Korsinsky.

    Review Our Privacy Policy

    FAX: 212-363-7171

    Levi & Korsinsky, LLP announces that a ZSAN class action lawsuit has been filed on behalf of investors who purchased Zosano Pharma Corporation (ZSAN) securities between February 13, 2017 and September 30, 2020. For more on the ZSAN Lawsuit please contact us today.

    According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company’s New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company’s lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.

    If you suffered a loss in you have until December 28, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.